Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

SIMPLE SUMMARY: Chronic lymphocytic leukemia (CLL) treatment scenario is rapidly evolving. As a consequence of longer observation, despite remarkable clinical results, treatment with ibrutinib is associated with long-term toxicities and resistance. New strategies based on BTK inhibition are under de...

Descripción completa

Detalles Bibliográficos
Autores principales: Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, Tedeschi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000925/
https://www.ncbi.nlm.nih.gov/pubmed/36900295
http://dx.doi.org/10.3390/cancers15051504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000925/
https://www.ncbi.nlm.nih.gov/pubmed/36900295
http://dx.doi.org/10.3390/cancers15051504

Ejemplares similares